PROMise,, has been initiated by the Cure Leukemia-funded Trials Acceleration Programme (TAP). PROMise, which is coordinated through the TAP hub at the Cancer Research UK Clinical Trials Unit (CRCTU) and financed by the University of Birmingham, was launched at University Hospital of Wales in Cardiff and Nottingham University Hospital. Over the next two years, the University Hospital of Wales and Nottingham University Hospital, along with 13 other NHS centers, will select MF patients to participate in a trial that provides a guaranteeing alternative to the existing course of care.
Stem cell transplantation is the sole cure for MF, which is only appropriate for a small number of younger individuals who do not have comorbidities. Treatment with ruxolitinib, which was licensed for usage in 2011 and is presently the only drug approved with an indication for MF, is the current NHS standard of care for people who cannot undergo stem cell transplant. Ruxolitinib is already widely used in clinical trials, although many individuals do not have a satisfactory response.
PROMise is a phase 1 clinical experiment that adds the innovative drug…
